Table 6. Prognostic factors for metastatic patients according to overall survival.

	Univariate analyses
	Overall survival(metastatic patients n=41)
	Evts/pts	HR	95% CI	P-valuea
Sex
Female vs male	34/41	1.08	0.54–2.17	0.82
Age in years
Continuous	34/41	0.99	0.97–1.02	0.64
>65 vs ⩽65	34/41	1.17	0.51–2.63	0.70
WHO PS
2 vs 0–1	29/34	8.52	2.92–24.9	<0.0001
Tumour differentiation
Poorly vs well and moderately differentiated	34/41	2.70	1.13–6.46	0.03
Primary site
Jejunum vs duodenum	34/41	0.60	0.25–1.40	0.24
Ileum vs duodenum	34/41	1.34	0.57–3.12	0.50
Baseline CA19-9 (IU ml−1)
>37 vs ⩽37	25/30	2.13	0.61–7.37	0.23
Baseline CEA (ng ml−1)
>5 vs ⩽5	30/36	0.84	0.29–2.43	0.74
Palliative chemotherapy
No vs yes	34/41	0.67	0.09–5.01	0.69
Dual therapy
No vs yes	33/39	4.27	0.85–21.6	0.08
Metastatic
Synchronous vs metachronous	34/41	2.35	1.07–5.19	0.03
P53
Overexpression vs normal	33/40	0.96	0.47–1.95	0.9
β-Catenin
Abnormal vs normal	34/41	1.05	0.45–2.43	0.91
MMR phenotype
dMMR vs pMMR	33/40	0.52	0.15–1.79	0.30
KRAS status
Mutated vs wild	26/30	0.35	0.14–0.83	0.02

	Multivariate analyses
	Overall survival N=26, events=23C index=0.734, likelihood ratio test=17.07 for 2 df, P<0.001
	HR	95% CI	P-value
WHO PS
2 vs 0–1	14.6	0.19–66.5	<0.001
KRAS status
Mutated vs wild	0.37	0.15–0.96	0.04

Abbreviations: CI=confidence interval; dMMR=mismatch repair deficiency; Evts=events; HR=hazard ratio; pMMR=proficient mismatch repair; PS=performance status; pts=patients; WHO=World Health Organisation.

^aLog-rank test.